Data from Pharmawand - Curated by EPG Health - Date added 14 March 2018

AbbVie announced that the Phase III ELARIS UF-II study (M12-817) of elagolix met its primary endpoint in women with uterine fibroids. Results from the second of two pivotal Phase III studies demonstrated at month six that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 76.2 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (10.1 percent), as measured by the alkaline hematin method.

Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.02) at month six. The overall safety profile for elagolix was consistent with what was observed in Phase II studies and the first Phase III study (ELARIS UF-I) in uterine fibroids. Data from the ELARIS UF-II Phase III study will support regulatory submissions for elagolix.

Safety data, including most common adverse events, continue to be collected in this ongoing study. The topline results from this six-month primary analysis were consistent with topline results from the ELARIS UF-I study reported in February 2018 and will be presented at an upcoming medical conference. Women in the study will continue in either post-treatment follow-up or a blinded six-month extension study.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Related Content